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ABSTRACT
The number of agents that are potentially effective in
the adjuvant treatment of locally advanced resectable
colon cancer is increasing. Consequently, it is important
to ascertain which subgroups of patients will benefit
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from a specific treatment. Despite more than two de-
cades of research into the molecular genetics of colon
cancer, there is a lack of prognostic and predictive mo-
lecular biomarkers with proven utility in this setting. A
secondary objective of the Pan European Trials in
Adjuvant Colon Cancer-3 trial, which compared iri-
notecan in combination with 5-fluorouracil and leu-
covorin in the postoperative treatment of stage III
and stage II colon cancer patients, was to undertake a
translational research study to assess a panel of puta-
tive prognostic and predictive markers in a large co-
lon cancer patient cohort. The Cancer and Leukemia
Group B 89803 trial, in a similar design, also investi-
gated the use of prognostic and predictive biomarkers
in this setting. In this article, the authors, who are co-
investigators from these trials and performed similar
investigations of biomarker discovery in the adjuvant
treatment of colon cancer, review the current status
of biomarker research in this field, drawing on their
experiences and considering future strategies for bio-
marker discovery in the postgenomic era. The Oncolo-
gist 2010;15:390–404
INTRODUCTION
Colorectal cancer (CRC) is a major cause of cancer mortal-
ity worldwide, with approximately 500,000 recorded
deaths from the disease in 2002 [1]. A significant propor-
tion of patients presenting with stage I, II, or III disease
(75% of patients) can be cured by surgical intervention,
with U.S. 5-year survival rate figures of 93.2%, 82.5%, and
59.5%, respectively, compared with only 8.1% for stage IV
disease [2]. Following resection, there is a considerable risk
for tumor recurrence in patients with stage III and high-risk
stage II disease, which can be significantly reduced by
treating with 5-fluorouracil (5-FU)-based adjuvant chemo-
therapy [3–5]. The addition of oxaliplatin to 5-FU–based
chemotherapy (5-FU, leucovorin, and oxaliplatin—the
FOLFOX-4 regimen) is now a standard adjuvant treatment
for colon cancer, with a higher 5-year disease-free survival
(DFS) rate (73.3% versus 67.4%) and significantly higher
overall survival (OS) rate at 6 years in stage III patients
(78.5% versus 76%), compared with 5-FU–based treatment
alone [6]. The combination of irinotecan with 5-FU failed
to result in a higher DFS rate than with 5-FU–based therapy
alone in the Pan European Trials in Adjuvant Colon Cancer
(PETACC)-3 and Cancer and Leukemia Group B
(CALGB) 89803 trials [7, 8].
In the absence of adjuvant therapy, approximately 50%
of colon cancer patients with resectable disease are cured by
surgery alone, whereas 50% relapse. Using adjuvant che-
motherapy following surgery rescues approximately 15%
of patients from the relapsing group. In current practice, the
majority of colon cancer patients receive treatment unnec-
essarily, either because they were cured or because they
will relapse despite treatment. It is therefore essential to
identify patients who will benefit from adjuvant therapy,
sparing others needless toxicity and the financial burden of
chemotherapy that will not work. The availability and ap-
plication of various treatment modalities in colon cancer
has resulted in intense interest in the elucidation of prog-
nostic and predictive biomarkers that will improve outcome
through patient classification and selection for specific
therapies. A prognostic biomarker provides information
about the patient’s overall outcome, regardless of therapy,
whereas a predictive biomarker gives information about the
effect of a particular therapeutic intervention. Currently, the
tumor–node–metastasis stage is the only proven prognostic
marker to aid in the identification of patients with aggres-
sive disease [3, 9]. Thus, there is an urgent need for prog-
nostic and predictive biomarkers to guide adjuvant therapy
for colon cancer and a need for large cohorts of randomized
patients in which to test and validate biomarkers in this set-
ting.
A secondary objective of the PETACC-3 trial was to un-
dertake a translational research study to assess a panel of
putative prognostic and predictive markers in a large colon
cancer patient cohort [10]. The preliminary findings of that
study and the status of other large randomized adjuvant tri-
als, including the CALGB 89803 trial, were reviewed and
placed in the context of biomarker discovery for adjuvant
treatment of colon cancer at a meeting of a panel of experts
held in Boston (U.S.) in May 2008 sponsored by Pfizer. In
this article, we review the current status of biomarkers for
the adjuvant treatment of colon cancer and consider future
strategies for biomarker discovery and development in the
postgenomic era.
BIOMARKERS IN COLON CANCER: PRESENT STATUS
Molecular Genetics of Colon Cancer
Our knowledge of the molecular etiology of colon cancer
has facilitated the identification of a number of promising
prognostic and/or predictive biomarkers. A simplified
model of tumor progression from adenoma to carcinoma
has been proposed, which includes the stepwise accumula-
tion of genetic events to several key genes and genetic loci:
disruption to WNT signaling, activation of the KRAS proto-
oncogene, allelic imbalance (AI) on chromosome 18q, re-
duced expression of SMAD4, and mutation of the TP53
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tumor suppressor gene [11–15]. A summary of the genes
involved in sporadic colon cancer development is shown in
Table 1. A more detailed molecular analysis of colon can-
cers revealed colon tumors to be heterogeneous with regard
to molecular alterations and potentially categorizable into
specific tumor phenotypes based on their molecular pro-
files. Two of these represent genetic instability classes. The
majority of sporadic cases (up to 85%) display chromo-
somal instability (CIN), which manifests as aneuploid and
polyploid karyotypes and multiple structural chromosomal
changes [12, 13, 16, 17]. This phenotype is thought to arise
through defects in a number of processes, including aber-
rant expression or mutation of mitotic checkpoint genes,
microtubule spindle defects, and telomere dysfunction [18].
In contrast, the remaining 15% of sporadic colon can-
cers demonstrate a microsatellite instability (MSI) pheno-
type, in which tumors display insertion–deletion mutations,
most commonly in short tandemly repeated nucleotides
(microsatellites) [19, 20]. Chromosome losses are rarer in
these tumors, which tend to have a diploid karyotype [17,
21]. The underlying genetic mechanism responsible for this
phenotype is loss of function, predominantly through gene
silencing of DNA mismatch repair (MMR) genes, in partic-
ular, MLH1 in sporadic CRC [22, 23]. Consequently, this
phenotype is also often referred to as the MMR deficient
(dMMR) phenotype, and in 2%–3% of CRC is caused by
germline mutations to one of a number of MMR genes
(MLH1, MSH2, MSH6, and PMS2) that form part of the pre-
sentation of Lynch syndrome, or hereditary nonpolyposis
CRC [24]. Whereas patients with an MSI/dMMR tumor
phenotype have a relatively stable karyotype, a deficient re-
pair process in tumors leads to loss of function mutations in
tumor suppressor genes, including TGFBR2, IGF2R, and
PTEN, and is associated with gain-of-function mutations in
oncogenes such as BRAF [25–27]; this phenomenon, in
turn, is often referred to as a “mutator” phenotype.
Finally, the analysis of CpG island methylation in the
silencing of genes in colon tumors has led to the identifica-
tion of the CpG island methylator phenotype, which ap-
pears to partially overlap the MSI phenotype [28, 29].
A summary of the clinical utility of a number of prom-
ising candidate markers in the adjuvant setting is presented
in Table 2 and reviewed below.
Genomic Instability Phenotypes as Biomarkers
MSI
MSI can be detected in tumors by a number of complemen-
tary approaches. Using the polymerase chain reaction
(PCR) to amplify specific microsatellite repeats, the pres-
ence of instability can be monitored through a comparison
of the length of repeats obtained from normal DNA (typi-
cally extracted from adjacent normal mucosa cells) with
those from the DNA extracted from the tumor cells. A ref-
Table 1. Genes commonly involved in sporadic CRC
Gene Protein function Defect in CRC Frequency (%)
APC Negative regulator of WNT signaling
involved in controlling cell
proliferation in the colon and small
intestine
Inactivation by mutations leading to loss
of function of APC protein (protein
truncation) and constitutive activation of
WNT signaling
85
MLH1 DNA single nucleotide mismatch
repair
Epigenetic silencing leading to loss of
protein expression and the accumulation
of cellular mutations
15–25
TP53 Transcription factor regulating
downstream target genes involved in
cell cycle regulation
Inactivating (nonsense and misense)
mutations leading to loss of function of
wild-type protein
35–55
SMAD4 Component of the TGF- signaling
pathway
Target of AI on chromosome 18q, gene
inactivation by homozygous deletion/
mutation
10–35
KRAS GDP/GTP binding protein
facilitating ligand dependent TK
growth factor signaling
Activation (most commonly through
codon 12/13 misense mutations) leading
to activation of the RAF–MEK–ERK
pathway
35–45
BRAF Serine–threonine protein kinase that
acts as a downstream effector of
KRAS-mediated signaling
Activation most commonly through a
valine-to-glutamic acid amino acid
(V600E) substitution
8–12
Abbreviations: AI, allelic imbalance; CRC, colorectal cancer; ERK, extracellular signal–related kinase; MEK, mitogen-
activated protein kinase/extracellular signal–related kinase kinase; TGF-, transforming growth factor ; TK, tyrosine
kinase.
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Table 2. Summary of studies investigating candidate genes and phenotypes as independent prognostic and predictive
biomarkers in adjuvantly treated colon cancer patients
Candidate
biomarker
Prognostic utilitya Predictive utilityb
General commentsIn favor Against In favor Against
Tumor MSI-H
phenotype
(or dMMR)
MSI-H is associated with longer
survival [32–34, 36, 40, 42,
107]
No evidence that
MSI-H is
associated with
longer survival
[152, 153]
MSI-H is associated with
longer survival in
patients receiving
adjuvant 5-FU–based
therapy than those
receiving surgery alone
[38, 61]
No evidence that MSI-H
is associated with longer
survival in patients
receiving adjuvant
therapy [33, 36, 39, 40,
42, 152]
MSI-H phenotype is largely
associated with good
prognosis
There is a call for patients
with stage II colon cancers
with MSI-H tumors to not
receive adjuvant
chemotherapy [39, 43]
The predicative value of the
MSI-H phenotype is being
tested in the ongoing E5202
adjuvant colon cancer trial
MSI-H is predictive of
response to irinotecan
plus 5-FU and LV in
stage III colon cancer
patients [41]
Tumor 18q AI 18q AI is associated with
shorter survival [45–48, 50, 51,
154]
No evidence that
18q AI is
associated with
shorter survival
[34, 49]
NR NR The prognostic and
predictive value of 18q AI
is being examined in the
ongoing E5202 adjuvant
colon cancer trial
Tumor p53
expression/
mutation
p53 mutation/overexpression is
associated with poor patient
prognosis—lower DFS [62],
RFS [66], and OS [67] rates
No evidence that
p53 status
provides
prognostic value
[63, 68]
p53 mutation and
overexpression is
associated with shorter
survival in patients
receiving 5-FU–based
adjuvant therapy [61, 67,
69]
No evidence that p53
status is predictive in
treated or untreated
patients [66, 70]
Different methodologies
have been used to assess
p53 status, making
comparison between studies
difficult
Tumor KRAS
mutation
KRAS mutation is associated
with shorter survival [69, 74,
75]
No evidence that
KRAS mutation
has prognostic
value [62, 77,
78, 80–84]
Wild-type KRAS patients
benefit from adjuvant
therapy [69]
CALGB 89803 study
suggests that KRAS gene
mutations are not
predictive of outcome
for patients receiving
adjuvant irinotecan plus
5-FU and LV.
Tumor KRAS mutation
status is not a prognostic
factor in large adjuvant
trials and in mCRC patients
receiving BSC [79]
KRAS mutation status is
predictive of outcome with
EGFR-targeted agents in
mCRC patients
Adjuvant trials (PETACC-
8) are under way to
investigate tumor KRAS
status in patient response to
EGFR-targeted agents
Tumor TYMS
expression
High TYMS expression is
associated with shorter survival
(mainly in patients receiving
5-FU–based adjuvant therapy)
[65, 66, 101–104]
High TYMS expression is
associated with longer survival
in patients receiving adjuvant
therapy [101, 102, 106]
Low TYMS expression is
associated with shorter survival
in patients receiving surgery
alone [105]
No evidence that
TYMS
expression has
prognostic value
[68, 107, 108]
High TYMS expression
is associated with longer
survival in patients
receiving 5-FU–based
adjuvant therapy [101,
102]
No evidence that High
TYMS expression is
predictive of response to
adjuvant therapy [66,
108]
TYMS expression has been
determined by a number of
different technologies—
RT-PCR, IHC (different
scoring systems used)—the
clinical value of TYMS
expression remains to be
determined
TYMS
genotypes
High TYMS expression
genotypes and haplotypes have
been associated with tumor
recurrence in patients with stage
II and stage III colon cancer
[113]
NR Low TYMS expression
genotypes in patients
treated with 5-FU–based
adjuvant therapy have
been associated with
longer survival [114]
NR The relationship between
germline variation and
TYMS gene function
remains to be elucidated
and the clinical value needs
to be further determined
High TYMS expression
genotypes have been associated
with longer DFS and OS in
patients receiving adjuvant
therapy [115]
Only studies from published (peer-reviewed) reports in which 100 patients were studied and in which biomarkers were shown to be independently
associated with clinical outcome are shown.
aPrognostic utility was assessed in relation to reported data from meta-analyses or analyses (retrospective and prospective) of patient clinical samples from
single-arm studies, large population- based studies, or large collaborative group studies.
bPredictive utility was assessed in relation to reported data from studies in which patients receiving adjuvant 5-FU–based chemotherapy and nontreated
patients were described and compared including: single randomized trials, large intergroup studies, and meta-analyses.
Abbreviations: 5-FU, 5-fluorouracil; AI, allelic imbalance; BSC, best supportive care; DFS, disease-free survival; dMMR, deficient mismatch repair; EGFR,
epidermal growth factor receptor; IHC, immunohistochemistry; LV, leucovorin; mCRC, metastatic colorectal cancer; MSI-H, microsatellite instability high;
NR, no published reports; OS, overall survival; PETACC, Pan European Trials in Adjuvant Colon Cancer; RFS, relapse-free survival; RT-PCR, reverse
transcription-polymerase chain reaction.
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erence panel of 5–10 microsatellite loci is used to diagnose
MSI cases [30], for which three categories have been estab-
lished: MSI-High (MSI-H), unstable for 30% of markers
used; MSI-Low (MSI-L), unstable for 10%–30% of mark-
ers used; and microsatellite stable (MSS), for cases that dis-
play no MSI. Lack of expression of MMR proteins as
assessed by immunohistochemistry (IHC) (primarily using
antibodies to the MLH1 protein) is diagnostic for dMMR
and is often used in MSI tumor analysis as an alternative to
PCR, and additionally in the clinical setting to complement
genetic testing for Lynch syndrome patients [24].
In clinical studies, MSI rates have been shown to vary
with tumor stage—22% reported in stage II, 12% reported
in stage III, and 2% reported in stage IV disease [31]. In the
adjuvant setting, MSI tumor status has been shown to be a
significant prognostic marker. The majority of retrospec-
tive studies (Table 2) demonstrate that patients with MSI-H
(or dMMR) colon cancers have higher survival rates than
those with MSS tumors [32–34]. These findings were con-
firmed in a meta-analysis of 32 trials, which confirmed the
prognostic advantage in patients with MSI-H tumors and
those treated with 5-FU–based adjuvant therapy [35]. In the
PETACC-3 study, the prognostic value of MSI status was
found to be more significant in patients with stage II disease
than in stage III cases [36]. In addition, in a multivariate
analysis of stage II colon cancer patients from the QUick
and Simple And Reliable (QUASAR) study, Kerr and col-
leagues demonstrated that MMR deficiency (hazard ratio
[HR], 0.31; 95% confidence interval [CI], 0.15–0.63; p 
.001) and T4 stage (HR, 1.94; 95% CI, 1.35–2.79; p .005)
(together accounting for 25% of patients) were independent
prognostic factors for tumor recurrence [37]. Similar find-
ings were reported in a multivariate analysis of the
PETACC-3 data [36].
The value of MSI tumor status as a predictive marker of
adjuvant therapy is less clear. An early study suggested that
MSI-H was predictive of response to 5-FU–based adjuvant
therapy in patients with stage III colon cancer [38]. How-
ever, an accumulating body of evidence suggests that pa-
tients with MSI-H tumors do not benefit from 5-FU–based
adjuvant therapy, compared with patients with MSS tumors
[33, 35, 39, 40]. This is particularly relevant for patients
with stage II disease, for whom adjuvant chemotherapy
(5-FU alone) is reported to increase survival by approxi-
mately 3%, and has led some investigators to recommend
that stage II colon tumors should be analyzed for dMMR
status to guide decisions on the use of adjuvant therapy
[39].
Recently the CALGB 89803 study reported a higher
5-year DFS rate in stage III colon cancer patients with
MMR-deficient/MSI-H tumors treated with irinotecan plus
5-FU than in patients treated with the same regimen with
intact MMR proteins: this was not observed in patients
treated with 5-FU and leucovorin (LV) alone, suggesting
that tumor MSI status might be predictive of response to iri-
notecan in stage III colon cancer [41]. In contrast, the
PETACC-3 study, in 1,327 patients, failed to demonstrate a
predictive effect of tumor MSI status for patients treated
with irinotecan, 5-FU, and LV, compared with those receiv-
ing 5-FU alone [36, 42].
To date, MSI is considered to be a strong and well-
validated prognostic marker in adjuvant CRC, and it is cur-
rently the only such biomarker in this setting. In the
appropriate clinical setting, we would advocate that MSI
data may be used in clinical decision making, particularly in
stage II colon cancers, for which a favorable outcome of pa-
tients with MSI-H tumors suggests that these patients
should not receive adjuvant chemotherapy [43]. The assess-
ment of MSI tumor status as a predictive marker for adju-
vant therapy requires more data. It should also be
considered, however, that the value of MSI tumor status as
a prognostic or predictive marker in the adjuvant setting
may be effected by mutations to other genes involved in co-
lon cancer etiology, such the BRAF gene (discussed below)
[44].
Chromosome 18q AI/CIN
Chromosome 18q AI has been associated with poor prog-
nosis in stage II and stage III CRC patients in some studies
[45–48], but not others [34, 49] (Table 2). Watanabe and
colleagues reported that patients with stage III MSS colon
tumors with no 18q AI had a higher survival rate following
5-FU–based treatment (70% versus 50%) than those whose
tumors displayed 18q AI [50]. In the CALGB 89803 study,
stage III colon cancer patients with 18q AI had lower 5-year
DFS (0.78 versus 0.93) and OS (0.85 versus 0.98) rates than
patients whose tumors displayed no 18q AI [51]. However,
drawing conclusions from comparing chromosome 18q AI
studies in colon cancer is difficult, and differences in the
methodologies used, including the scoring of AI, possibly
explains the contradictory findings reported. Thus, the in-
consistency of the genetic markers used among studies leads to
analysis of AI in different regions on chromosome 18q.
An additional complication comes from the stage-spe-
cific effects of biomarkers. The PETACC group presented,
at the 2009 American Society of Clinical Oncology Annual
Meeting [36], that tumor 18q AI status was not found to be
prognostic in stage II tumors, whereas an effect was found
in stage III tumors on univariate analysis. This is important
because the patient population most in need of prognostic
markers is stage II patients, for whom treatment versus no
treatment is based on the inherent prognostic features. Cur-
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rently, in the E5202 clinical trial (discussed below) [52],
18q AI status is being used to differentiate between low-
and high-risk stage II tumors in an extrapolation of the stage
III data, which in reality may not be biologically correct. In
addition, when the PETACC group evaluated the effect of
18q loss of heterozygosity (LOH) in univariate, compared
with multivariate, models (containing MSI and tumor node
status), it was found that 18q LOH status lost significance if
MSI was included in the model [36], suggesting that these
markers do not act independently and correct prognostica-
tion will have to take into account several markers.
A further problem in assessing tumor 18q AI status is
determining what is actually being measured by 18q AI,
which is currently generally unclear. Unless carefully ana-
lyzed, AI can be scored as the consequence of a number of
different genetic events arising from different molecular
causes, with possibly different functional and biological
consequences. Thus, AI may be generated by loss or gain of
chromosomal material. Where loss is the proven mecha-
nism of the AI, the assumption commonly made is that the
clinical significance is a result of the loss of function of spe-
cific genes within the chromosomal region (SMAD7,
SMAD4, DCC, and SMAD2). If this is indeed the case, then
18q AI association studies should incorporate data derived
from quantitative assays measuring target gene or protein
expression, as has been reported in metastatic CRC
(mCRC) for SMAD4 [53]. In stage III colon cancer, lower
expression of SMAD4 was reported to be associated with
poor prognosis in patients treated with 5-FU–based chemo-
therapy [54–56].
However, it is also possible that chromosome 18q AI
may simply be a surrogate marker for the complex CIN phe-
notype found in the majority of colon tumors [57, 58]. Thus,
AI assays restricted to chromosome 18q are not able to dis-
criminate between 18q-related gene-inactivation events
and more general aneuploidy (a characteristic of CIN,
which may also nevertheless lead to the inactivation or dim-
inution of 18q gene function). This has implications in re-
lation to our understanding of the contribution of
chromosome 18q imbalance to colon tumor biology and re-
sponse to therapy, and its role as a biomarker. Thus, tumor
phenotypes might be masked or conflated using one tech-
nology to assess imbalance at 18q, which may in turn ex-
plain the contradictory findings on 18q AI and prognosis in
colon cancer in the literature [34, 45, 46, 49].
Examining CIN as a prognostic marker in colon cancer
has proven difficult, first because the phenotype is poorly
defined and second because a number of different technol-
ogies, including AI, flow cytometry, and array-based com-
parative genomic hybridization (a-CGH), have been used to
measure CIN. A recent meta analysis of 63 studies (10,126
CRC patients of all stages) found CIN to be associated with
a worse prognosis in CRC, including patients with locally
advanced disease [59]. In that analysis, CIN was assessed in
studies using techniques to measure chromosome ploidy
(flow cytometry and image analysis), and hence the data in-
clude chromosome 18 numerical alterations. Further, the
predictive value for patients receiving 5-FU–based chemo-
therapy could not be determined. The authors called for
CIN to be evaluated as a prognostic marker together with
MSI status in clinical trials of colon cancer patients involv-
ing adjuvant therapy.
Candidate Genes as Biomarkers
A number of important colon cancer genes have been iden-
tified and extensively studied as candidate biomarkers
in colon cancer in the adjuvant setting and are reviewed
below.
TP53
The TP53 gene encodes a transcription factor, and in re-
sponse to a variety of cellular stresses, including DNA dam-
age, activated TP53 protein binds to the regulatory
sequences of a number of target genes to initiate a program
of cell cycle arrest, DNA repair, apoptosis, and angiogene-
sis [60]. Loss of function of TP53 is critical in tumorigen-
esis, and alterations to the TP53 gene (mutations, often
resulting in protein overexpression) are frequent events in
colon cancer, often associated with the CIN phenotype and
inversely correlated with the MSI tumor phenotype [61,
62]. Associations of TP53 tumor alterations with patient
prognosis and response to adjuvant chemotherapy have
been widely studied, and findings are contradictory (Table
2) [63, 64]. For example, TP53 protein expression and gene
mutation have been associated with poor prognosis in colon
cancer patients, although other studies report no prognostic
value [63, 68]. In clinical studies in which adjuvant chemo-
therapy–treated and nontreated groups could be analyzed,
stage III CRC patients whose tumors demonstrated no TP53
alterations experienced significantly longer survival fol-
lowing 5-FU–based chemotherapy than patients whose tu-
mors overexpressed p53 [61, 67, 69]. However, other
studies in colon cancer patients failed to demonstrate cor-
relations between TP53 alterations and benefit from adju-
vant therapy [66, 70]. The contradictory nature of these
studies may reflect differences in the methodologies used to
assess TP53 status, including different antibodies used to
detect the protein (with varying sensitivities for wild-type
or mutant protein), different immunostaining techniques,
and different scoring systems used for assessing expres-
sion. Indeed, the reported value for TP53 overexpression in
the literature covers a wide range (27%–76%), which may
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reflect these issues. It is generally accepted that the detec-
tion of p53 protein by IHC is a poor indicator of TP53 gene
mutation status, because alternative molecular mechanisms
can lead to protein stabilization in tumors, and some muta-
tions lead to loss of protein stability [71]. Studies in which
TP53 mutations were detected by gene sequencing report
associations with poor prognosis in colon cancer patients
[62, 67, 72]. It has been suggested that, to analyze the gene
properly in clinical studies, TP53 mutation status should be
assessed by DNA sequencing and data must be combined
with TP53 protein expression information as determined by
IHC.
KRAS
The KRAS proto-oncogene encodes a 21-kDa guanosine
triphosphate/guanosine diphosphate binding protein in-
volved in facilitating cellular response to extracellular stim-
uli. Mutations within the KRAS gene (primarily at codons
12 and 13) abrogating GTPase activity and leading to
downstream activation of RAS/RAF signaling are common
(35%–42%) and early events in colon tumorigenesis [73].
However, the role of KRAS mutation status as a prog-
nostic and predictive biomarker in the adjuvant setting is
controversial (Table 1). In a large meta-analysis, codon 12
glycine-to-valine mutations were found to be prognostic in
patients with stage III disease [74, 75]. Smaller studies have
shown KRAS mutation status to be associated with poor
prognosis in patients with stage II [76] and stage III disease
[69, 74, 75]. However, recent analyses from the CALGB
89803 (stage III colon cancer) and PETACC-3 (stage II and
III) trials demonstrated KRAS mutation to not be a prognos-
tic marker for patients treated with adjuvant 5-FU–based
chemotherapy [77, 78]. In addition, the National Cancer In-
stitute of Canada CO.17 trial recently demonstrated that tu-
mor KRAS mutation status had no prognostic effect for OS
in pretreated stage IV patients receiving best supportive
care [79].
As a predictive marker in the adjuvant setting, most
studies report no association between KRAS mutations and
response to standard chemotherapy [62, 80 – 83]. In a
Southwest Oncology Group trial, patients with stage III tu-
mors with KRAS mutations gained no additional benefit
from receiving 5-FU/LV compared with observation or LV
alone. In contrast, patients with KRAS wild-type tumors sig-
nificantly benefited from 5-FU/LV therapy [69]. Data from
the CALGB 89803 study suggest that KRAS tumor muta-
tion status is not prognostic or predictive for treatment with
irinotecan plus 5-FU and LV in stage III colon tumors [84].
In contrast, because of the central role of KRAS down-
stream in the EGFR signaling pathway, there is currently
intense interest in KRAS mutation status as a predictive bio-
marker in patients with advanced CRC treated with thera-
pies targeted to EGFR. KRAS gene mutations activate the
EGFR signaling pathway independently of ligand stimula-
tion of the receptor, and thus bypass the efficacy of EGFR-
targeting drugs. Single-arm studies [85– 87] and large
randomized studies in first-line [88, 89] and in previ-
ously treated [79, 90] mCRC patients have demonstrated
KRAS tumor mutations to be predictive of a lack of re-
sponse to the EGFR-targeted antibodies cetuximab and
panitumumab. It is now common practice to reserve
treatment with EGFR-targeting agents to wild-type
KRAS CRC patients.
BRAF
The BRAF gene encodes a serine–threonine protein kinase
that acts as a downstream effector of KRAS signaling and
belongs to the RAS–RAF–mitogen-activated protein ki-
nase/extracellular signal–related kinase kinase (MEK)–
extracellular signal–related kinase (ERK) kinase pathway
[91]. BRAF gene mutations are important in colorectal tu-
morigenesis [91, 92]. The most frequently reported BRAF
tumor mutation is a valine-to-glutamic acid amino acid
(V600E) substitution that leads to the aberrant activation of
the MEK–ERK pathway [93]. BRAF and KRAS mutations
tend to be mutually exclusive events in tumors [94], with
BRAF mutations occurring more frequently in MSI than in
MSS tumors [44, 95].
In patients with stage IV CRC, BRAF mutations have
been reported to be associated with poor prognosis [96],
and in chemotherapy-refractory mCRC patients BRAF mu-
tations have been reported to be predictive of a lack of re-
sponse to EGFR-targeted agents [96]. In stage II and stage
III colon cancer patients in the PETACC-3 study, BRAF
mutations occurred in 7.9% of tumors and were found to not
be prognostic of relapse-free survival, but they were prog-
nostic for OS, particularly in patients with MSI-L and MSS
tumors (HR, 2.2; p .0003) [77]. Other retrospective stud-
ies have also demonstrated an association between BRAF
mutation and poor prognosis in stage II–III [44] and stage
I–IV [97] CRC patients. Interestingly, in those studies the
good prognosis associated with patients with MSI-H tu-
mors was abrogated in the presence of coincident BRAF
mutations [44, 97].
In the adjuvant setting, BRAF mutation status appears to
be a valid prognostic marker; however, associations of
BRAF tumor mutations with different molecular subgroups
may have to be considered in order to assess the impact of
BRAF mutation status as a predictive marker for treatment
in future studies in this setting.
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TYMS
The thymidylate synthase gene TYMS encodes a key en-
zyme for pyrimidine biosynthesis and is an essential com-
ponent of the DNA synthesis pathway. TYMS protein
activity is inhibited by 5-FU (a pyrimidine analog), leading
to cell cycle arrest and apoptosis [98]. In vitro data indicate
that TYMS expression is a determinant of 5-FU sensitivity,
suggesting that the expression of the gene may also deter-
mine tumor sensitivity in vivo [99, 100]. However, conflict-
ing data make the role of this gene as a prognostic or
predictive marker in the adjuvant setting controversial (Ta-
ble 2). High levels of tumor TYMS protein are reported to
be associated with poor prognosis in CRC patients, partic-
ularly in those receiving surgery alone, although the rea-
sons for this remain unclear [65, 66, 101–104]. Study of the
expression of other enzymes in the pyrimidine biosynthesis
pathway— dihydropyrimidine dehydrogenase (DPD) and
thymidine phosphorylase—has shown low tumor expres-
sion of TYMS and DPD to be associated with worse prog-
nosis in stage II and stage III CRC patients treated with
surgery alone [105]. Patients receiving adjuvant 5-FU–
based chemotherapy with high levels of tumor TYMS ex-
pression were reported to experience significantly longer
survival times [101, 102, 106], with TYMS expression re-
ported to be predictive of response to adjuvant chemother-
apy [101, 102]. However, other studies found no prognostic
[68, 107, 108] or predictive [66, 108] value of response to
adjuvant chemotherapy for TYMS expression in colon
cancer.
Some studies have investigated TYMS mRNA levels in
tumors, and high levels of tumor TYMS mRNA and failure
to respond following 5-FU–based chemotherapy have been
reported [109, 110]. Germline variants in the TYMS gene
have been shown to alter TYMS protein and gene expres-
sion [111, 112], and have been associated with response,
time to tumor progression, OS, and time to tumor recur-
rence after 5-FU–based chemotherapy, although the data
are conflicting [113–115]. The clinical significance and re-
lationships between mRNA and protein levels in tumors
and between germline variation and TYMS gene function
remain to be elucidated in colon cancer.
The Use of Randomized Clinical Trials for
Biomarker Validation in Adjuvant Colon
Cancer: The PETACC-3 Study
The PETACC-3 trial encompassed a translational study to
validate current candidate biomarkers in a large colon can-
cer cohort of 3,278 patients. The main aims of the transla-
tional study were: (a) to assess the feasibility of biomarker
analysis on archival formalin-fixed, paraffin-embedded
(FFPE) material collected prospectively from 368 collabo-
rating centers in 31 European countries, (b) to evaluate or
confirm the prognostic relevance of selected biological
markers using 3-year DFS and OS endpoints, and (c) to as-
sess the predictive utility of specific markers in patients re-
ceiving irinotecan in combination with 5-FU and LV,
compared with those receiving 5-FU and LV alone [10, 36,
42].
FFPE tissue blocks were available from 1,564 patients
and were processed in a central laboratory, where 20–25
sections were cut per patient tissue block for subsequent
analysis. Biomarkers were assessed using validated and ro-
bust methodologies [10]. All data were collected and ana-
lyzed at the Swiss Group for Clinical Cancer Research.
Biomarker data were available from 1,452 cases, with
1,401 evaluable for matched normal and tumor tissue. The
success rate for the number of samples evaluable for spe-
cific markers was high:80% for IHC analysis and95%
for DNA mutation analysis using techniques optimized for
use on degraded DNA extracted from FFPE tissues. The
frequency of specific biomarker alterations in the
PETACC-3 study was consistent with that found in the lit-
erature [10], with sufficient statistical power to detect an
HR of 0.7 for DFS if the proportion of single-marker detec-
tion is 80% [10, 116]. Thus, a reassessment of the signifi-
cance of TP53 mutation and IHC, KRAS mutation, TYMS
genotype and IHC, and MSI in this cohort is ongoing [36,
42, 77], on which many of the same biomarkers are being
tested [8, 41, 51, 78]. Clearly, these two studies provide
useful independent test and validation cohorts of patients in
which to investigate candidate biomarker utility.
The Current Status of Biomarkers in Adjuvant
Colon Cancer: A Summary
Extensive colon cancer research over the last decade has
provided some promising biomarkers. In some cases, we
are close to using these in meaningful prospective clinical
studies. For example, the E5202 study is currently deter-
mining the role of MSI and 18q AI as predictive factors to
guide decision making for stage II colon cancer patients. In
that trial, the risk for relapse after adjuvant treatment for
stage II CRC is being assessed based on initial stratification
by MSI status and 18q AI; low-risk patients are subject to
observation whereas high-risk cases receive FOLFOX and
bevacizumab [52]. Other candidate biomarkers are a long
way from having their utility in the clinical setting con-
firmed, with many of the studies providing evidence of their
suitability being limited by the following common features:
1. Many studies are retrospective analyses of single-arm
investigations performed in small and often heteroge-
neous cohorts of patients in which rectal tumors have
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been examined together with colon tumors, and patients
have not been stratified by stage, gender, or age. Thus,
many have been statistically underpowered to provide
meaningful results. Using large cohorts of patients, such
as those in the PETACC-3 and CALGB 89803 trials,
may address many of these issues and provide an accu-
rate assessment of the prognostic and predictive (of re-
sponse to irinotecan-based treatment) capabilities of the
promising biomarkers described.
2. In many studies, a lack of standardization of methodol-
ogies for marker measurement has resulted in data that
are not comparable. It is hoped in the approaches used in
the PETACC-3 [116] and CALGB 89803 studies to cen-
tralize and standardize sample handling and methodolo-
gies that these important issues will be addressed.
3. Often, the methodology chosen in studies does not rep-
resent a comprehensive analysis of multiple components
of a specific biological pathway, each of which may in-
cur defects in multihit tumorigenesis. Significant asso-
ciations between molecular lesions in a pathway and
clinical parameters may therefore be missed. A prime
example of this is the analysis of chromosome 18q in co-
lon cancer patients undergoing adjuvant treatment. It is
recommended that future studies employ methods that
can discriminate among different molecular patholo-
gies, such as combinations of a-CGH, single nucleotide
polymorphism (SNP) arrays, and other methods that de-
tect DNA ploidy. The concurrent consideration of gene
or protein expression data for candidate genes on 18q
might also be necessary to demonstrate meaningful
associations.
4. Often, not all mutations within a given gene are
screened. An example is the KRAS gene, for which the
frequently occurring mutations at codons 12 or 13 are
measured but other, less common, mutations at codons
61 and 146 are not assessed. This can also be a source of
potential bias in an investigation. Furthermore, other
candidate genes in related signaling pathways will need
to be examined to provide a pathway-centric approach to
make sense of some of the observations made with single
candidate genes. For example, KRAS mutation status
should be judged in conjunction with the PI3K–AKT axis
because there is extensive crosstalk between these path-
ways [117].
Studies to date have demonstrated the urgent need for
biomarker development and have highlighted the method-
ological challenges of this research. Attempts have been
made to provide guidelines for the validation and optimiza-
tion of biomarkers for use in the clinical setting, prime ex-
amples being: the tumor marker utility grading system
(TMUGS) [118]; reporting recommendations for tumor
marker prognostic studies (REMARK) [119]; guidelines
for gene expression localization experiments; and the min-
imum information specification for in situ hybridization
and immunohistochemistry experiments (MISFISHIE)
[120].
FUTURE CONSIDERATIONS FOR BIOMARKER
INVESTIGATIONS IN THE ADJUVANT SETTING IN THE
POSTGENOMIC ERA
In this postgenomic era, technological developments have
occurred in which the whole genome can be rapidly and
cost-effectively investigated with high-throughput ap-
proaches. We now review how a combination of functional
genomics and molecular profiling in conjunction with care-
fully designed clinical trials can be applied to identifying
biomarkers and provide a vision for the future for adjuvant
colon cancer.
Postgenomic Technologies
A number of technology platforms have been developed to
detect genomewide alterations in tumors. These tools also
have the potential to provide predictive profiles for patient
prognosis and response to chemotherapy and are being ap-
plied to CRC in general. Gene expression microarrays al-
low the analysis of global gene-expression patterns in
mRNA extracted from tissue samples. Changes in tumor
DNA copy number have been traditionally characterized
using a-CGH, based on bacterial artificial chromosome
construct probes [58, 121]. Although copy number–depen-
dent AI and copy number–neutral AI have been assessed by
SNP microarrays [57], often the two technologies are com-
bined to allow a more precise definition of the molecular
basis of AI events occurring in tumors [57]. It has also been
reported that SNP-bead arrays can discriminate between
both copy number–dependent and copy number–neutral AI
events [122, 123]. Furthermore, with the development of
high-throughput gene sequencing and mutation detection
capabilities, a detailed picture of the mutation spectrum of
many genes in individual tumors can be realistically
achieved [124]. Recently, many of these technology plat-
forms and methods were adapted for use with DNA or RNA
extracted from FFPE tissues [123, 125–127]. Following the
identification of candidate genes of interest through expres-
sion profiling, the feasibility of developing quantitative re-
verse transcription PCR assays for use on FFPE material
from colon cancer patients in a clinical setting was demon-
strated [128]. These developments are important for bi-
omarker validation in large retrospective analyses, in
which FFPE material is often the only tissue available for
study.
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Hypothesis-Driven Candidate Gene Approaches
Whereas postgenomic technologies offer powerful tools for
biomarker discovery and validation, significant challenges
must be met in order for these methodologies to produce
changes in clinical practice. Hypothesis-driven approaches
seek to correlate molecular alterations of functionally rele-
vant genes (cell cycle, apoptosis, drug metabolism) with pa-
tient groups classified by clinical parameters (e.g.,
responders to chemotherapy versus nonresponders). In the
PETACC-3 study, such an approach might be to identify
genes or molecular profiles that are thought to be associated
with response to irinotecan. Thus, in mCRC, the UK MRC
FOCUS trial of chemotherapy for bowel cancer [Fluoro-
uracil, Oxaliplatin, and Irinotecan (CPT11) Use and Se-
quencing] demonstrated that patients whose tumors express
high levels of topoisomerase 1 protein (a target for irinote-
can) gain significantly more clinical benefit from receiving
irinotecan with 5-FU and LV first line, compared with pa-
tients whose tumors are low or negative for topoisomerase 1
[129]. Yu and colleagues examined the expression of 24
genes involved in the irinotecan pathway in matched nor-
mal and tumor tissues from 52 patients with Dukes’ C CRC
[130]. They found that patients could be classified into
three groups based on statistically significant differences in
the levels of gene expression, and concluded that expres-
sion profiling of the irinotecan pathway genes may be valu-
able for predicting response to irinotecan-based therapy in
colon cancer patients [130].
In similar approaches, cell lines have been used as in
vitro models for drug sensitivity, with candidate genes
identified by microarray analysis (differentially expressed
transcripts) and gene knockdown technologies. This ap-
proach has led to the identification of potential predictors of
taxane response in breast cancer [131, 132], and to the es-
tablishment of the CINATRA trial (Chromosomal Instabil-
ity and Anti-Tubulin Response Assessment, EudraCT no
2006–006073-240) to identify predictors of response to the
microtubule-stabilizing agent epothilone 906 in mCRC pa-
tients [133]. Similar strategies have described integrated
genomic-based approaches to identify oncogenic pathways
to predict sensitivity of cancer patients to specific chemo-
therapy regimens [134–137].
Genomic Profiling
There is clear heterogeneity in the biology of CRC tumors
classified by clinical parameters; thus, in stage II disease
some patients appear to have a higher risk for tumor recur-
rence following surgery. This suggests heterogeneity
among individual patients in the molecular pathways dis-
rupted in tumors, and data from early rectal cancer trials
support this idea [122]. This would explain why, after 20
years of research, there remains a paucity of molecular bio-
markers in the clinical setting. A strategy to identify more
useful biomarkers might therefore be to reclassify patients
into subgroups based on the similarities of their tumor mo-
lecular profiles using microarray or other genomic-profil-
ing technologies.
Using this approach, investigators have interrogated mi-
croarray data using unsupervised hierarchical clustering
analysis, in which patients are grouped according to the
similarity of their gene-expression profiles. This was pio-
neered in early breast cancer, for which the intrinsic sub-
type gene-expression model classifies breast tumors into
subgroups with different clinical outcomes [138, 139]. Sub-
sequently, several validated tumor genomic profiles associ-
ated with relapse in early breast cancer patients were
reported [139 –145]. In addition, five gene expression–
based models were compared in a single data set of 295 pa-
tients, in which the 70-gene set and recurrence score (RS)
models demonstrated 77%– 81% agreement in their out-
come predictions for individual samples, suggesting that
they may be tracking a common set of biological pheno-
types [146]. However, that study was limited because the
data set used for comparison was also used to develop one
of the expression signatures, and secondly, it was under-
powered for comparing similar signatures. More recently, a
large meta-analysis of publically available breast cancer
gene expression and clinical data, comprising 2,833 breast
tumors, demonstrated how prognostic signatures can be
successfully computed on different microarray platforms
using a simple approach [147], and confirmed the prognos-
tic values of these signatures, revealing that many of them
are broadly equivalent because of the inclusion of genes as-
sociated with cellular proliferation [148]. Finally, for the
best prognostic value, it was shown that gene-expression
values should not be used in isolation but combined with
clinical variables that measure the extent of tumor progres-
sion, such as tumor size and nodal status [147]. We antici-
pate that this experience will be of great value when
crosstrial comparisons of genomic and expression data are
performed in CRC patients.
In colon cancer studies in the adjuvant setting, genomic
profiling identified a 23-gene signature reported to predict
recurrence in colon cancer patients with Dukes’ B disease,
yielding a 78% prognosis prediction accuracy [149]. This
was validated in an independent study that yielded a 67.7%
mean prognosis profile [150] and identified a 30-gene ex-
pression profile that produced highly variable prediction
accuracy across training and validation sets. The authors
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concluded that microarray expression profiling is able to
predict, to some extent, prognosis in stage B colon cancer
patients and that resampling techniques should be used to
objectively assess the performance of microarray-based
prognosis predictors [150].
More recently, a multivariate analysis (including stage,
grade, nodes, and MSI status) of four developmental studies
in colon cancer patients identified 18 genes (seven prognos-
tic genes and six genes predictive for 5-FU and LV benefit,
and five reference genes) and separate prognostic RS and
treatment predictive score (TS) algorithms [37]. In a vali-
dation analysis on material from the QUASAR study, the
RS was validated as an independent predictor of individu-
alized recurrence risk for stage II colon cancer patients, al-
though the TS was not validated as a predictor of benefit
from 5-FU and LV therapy [37].
Although studies in colon cancer are promising, caution
is required because investigators have yet to meet the high
standards for study reproducibility and generalizability re-
quired for the use of genomic profiling in the classification
of cancer patients for clinical purposes (reviewed by
Michiels et al. [151]). Robust prediction rules must be de-
veloped in order to correlate gene-expression profiles with
clinical outcome. A major question to be addressed with
this approach is whether or not gene-expression profiles im-
prove on existing prognostic systems. In breast cancer, clin-
ical trials have been established to determine the prognostic
and predictive values of gene-expression profiles. In the
TAILORx study [Trial Assigning IndividuaLized Options
for Treatment (Rx)], the National Cancer Institute is inves-
tigating the breast cancer RS model in 10,000 women re-
cruited across the U.S. and Canada with estrogen receptor–
and/or progesterone receptor–positive, human epidermal
growth factor receptor 2/neu-negative breast cancer that has
not yet spread to the lymph nodes. The European Organi-
zation for Research and Treatment of Cancer has designed a
trial (Microarray In Node negative Disease May Avoid
ChemoTherapy, MINDACT) to study the 70-gene signa-
ture in 6,000 node-negative breast cancer patients recruited
across Europe. The design of similar trials will be the gold
standard for the investigation of the prognostic and predic-
tive value of genomic profiles in adjuvant colon cancer.
CONCLUSIONS
Despite significant methodological progress, CRC re-
search has not yet provided biomarkers for clinical use in
guiding adjuvant colon cancer treatment, although MSI
is promising. Preliminary biomarker data from the
PETACC-3 and CALGB 89803 trials suggest that it is
possible to perform translational studies on FFPE mate-
rial derived from large multicenter clinical trials carried
out in the adjuvant setting. Furthermore, the approaches
used provide a model for use in the laboratory of material
collected during the course of other randomized adjuvant
studies. Although the development of platforms for
genomewide analysis of molecular alterations in tumors
will facilitate biomarker discovery, it is important that
our studies are not driven primarily by the availability of
superior technology. The selection of hypotheses for
testing must be guided in the first instance by putative
clinical relevance, irrespective of whether the questions
are focused on increasing our understanding of tumor bi-
ology or are part of patient reclassification/treatment se-
lection procedures. Ultimately, the end product of a
translational study must be a clinically relevant biomar-
ker that can be easily assayed in the clinical setting, pro-
ducing a direct benefit for the individual patient.
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